Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Switching From Direct Oral Anticoagulants to Low Molecular Weight Heparin in Cancer Patients With Atrial Fibrillation During Antineoplastic Therapy

Next Previous
X
Search
Trial Profile

Safety and Efficacy of Switching From Direct Oral Anticoagulants to Low Molecular Weight Heparin in Cancer Patients With Atrial Fibrillation During Antineoplastic Therapy

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bemiparin sodium (Primary) ; Dalteparin sodium (Primary) ; Enoxaparin sodium (Primary) ; Fondaparinux sodium (Primary) ; Nadroparin calcium (Primary) ; Tinzaparin sodium (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Stroke
  • Focus Therapeutic Use
  • Acronyms MAFIC

    • Most Recent Events

    • 30 Jul 2024 Status changed from recruiting to withdrawn prior to enrolment.
    • 07 Feb 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (Last Verified Feb 2022)
    • 14 Feb 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top